The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus

Nakakubo, Yoshihiro; Hida, Yasuhiro; Miyamoto, Masaki; Hashida, Hideaki; Oshikiri, Taro; Kato, Kentaro; Suzuoki, Masato; Hiraoka, Kenzo; Ito, Tomoo; Morikawa, Toshiaki; Okushiba, Shunichi; Kondo, Satoshi; Katoh, Hiroyuki

doi:10.1016/s0304-3835(01)00773-x

Cited by 37 publications

(36 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Others reported that RCAS1 is associated with poor prognosis and/or advanced stage in various human cancers (Sonoda et al, 1996;Kaku et al, 1999;Izumi et al (2001); Nakakubo et al, 2002). However, the expression of EBAG9 and its clinical significance have not been examined in epithelial ovarian cancer.…”

mentioning

confidence: 99%

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Aoki

Suzuki

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7 human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the present study, we examined the expression of EBAG9/RCAS1 in human epithelial ovarian cancer using immunohistochemistry, immunoblotting and reverse transcription -polymerase chain reaction (RT -PCR). A total of 90 epithelial ovarian cancer cases were examined immunohistochemically by means of the antibodies for EBAG9 and ERa. The correlation between EBAG9 immunoreactivity and clinicopathological parameters was examined. mRNA expression of EBAG9 and ERa were evaluated by RT -PCR in 22 cases. The expression for EBAG9 and ERa was examined by immunoblotting in 12 ovarian cancer cell lines. EBAG9 immunoreactivity was detected in the surface and cytoplasm of carcinoma cells in 46 out of 90 cases (51.1%). EBAG9 expression was significantly higher in serous histology (P ¼ 0.0402) and advanced disease (P ¼ 0.0206). No significant relationship was detected between EBAG9 immunoreactivity and overall survival (P ¼ 0.689). There was a highly significant correlation between EBAG9 and ER immunoreactivity (Po0.0001). The EBAG9 mRNA was detected in 20 out of 22 cases. In all of the cases that were positive for ERa mRNA, they were also positive for EBAG9 mRNA. Immunoreactive band corresponding to EBAG9 was detected in 11 out of 12 of ovarian cancer cell lines, and was consistent with ERa expression. In conclusion, the wide distribution of EBAG9 and its relation to advanced disease suggest that this protein may play important roles in epithelial ovarian cancer.

show abstract

mentioning

confidence: 99%

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Aoki

Suzuki

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Serum RCAS1 level increased significantly in GI tract tumours with lymph node involvement; however, it was not correlated with tumour grade, serosal and vascular invasion or distant metastasis. RCAS1 expression has been demonstrated with immunohistochemical analysis in esophagus, gastric and colorectal cancers (6,21,22). Its expression has been reported to be associated with aggressive tumour behaviour.…”

Section: Discussionmentioning

confidence: 99%

“…Nakakubo et al (21) investigated the immunoreactivity of RCAS1 and its correlation with clinicopathological features in 95 patients who underwent surgical resection for esophageal squamous cell carcinoma. However, the expression was examined by histochemical staining rather than serum analysis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Utility of Serum Receptor-Binding Cancer Antigen Expressed on Siso Cells in Gastrointestinal Tract Cancers

Özkan

Köklü²,

Yüksel

et al. 2006

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

BACKGROUND: Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) is a novel tumour marker that has been described in various kinds of cancer. The majority of observations include immunohistochemical studies; however, there are not enough data about the utility of this antigen as a serum tumour marker and its tumour specificity. AIM: To measure the serum levels of RCAS1 in patients with gastrointestinal (GI) tract cancers and compare them with other GI tract tumour markers. PATIENTS AND METHODS: Sera collected from patients with GI cancers (14 esophagus, 32 gastric and 36 colon) and from healthy volunteers (30 individuals) were analyzed for RCAS1 and compared with carcinoembryonic antigen (CEA) and cancer antigen 19-9. The relationship between serum RCAS1, tumour stage and tumour grade was also evaluated. RESULTS: Mean serum RCAS1 level was higher in patients with GI tract cancers compared with the control group (P=0.001). Among GI tract cancers, RCAS1 had lowest and highest sensitivity for esophagus and colon cancer diagnosis, respectively. Serum RCAS1 had a higher sensitivity for malignancy, except in the colon, and lower specificity in all groups compared with CEA. In comparison with cancer antigen 19-9, serum RCAS1 was more sensitive but less specific for all GI cancer groups. Mean serum RCAS1 levels were not statistically significant among histopathological tumour types (P>0.05). Although serum RCAS1 levels were significantly higher in cases with lymph node involvement compared with lymph node-negative cases (P=0.009), there was no difference between cases with and without serosal involvement, vascular invasion and distant metastasis; no correlation was found between tumour size and RCAS1 levels. CONCLUSIONS: RCAS1 may be used and combined with CEA as a tumour marker in GI tract cancers.

show abstract

“…RCAS1 has also been detected in nongynecological cancers such as human breast carcinomas [26,32,36], esophageal squamous cell carcinomas [19], gastric adenocarcinomas [6,16], hepatocellular carcinomas [2,21], lung cancers [13,14,22], and pancreatic adenocarcinomas [1,19]. Expression of RCAS1 is associated with a poor prognosis in these cancer patients.…”

mentioning

confidence: 99%

Expression of a Tumor-Associated Antigen, RCAS1, in Canine Mammary Tumors

et al. 2004

View full text Add to dashboard Cite

ABSTRACT. Receptor-binding cancer antigen expressed on SiSo cells (RCAS1), one of novel cancer cell-surface antigens, is strongly expressed in invasive cancers. RCAS1 inhibits the in vitro growth of lymphocytes such as T cells and natural killer (NK) cells, and induces apoptotic cell death. We investigated the expression of RCAS1 in canine mammary tumor cell lines and tumor cells by immunohistochemistry, and also in situ deoxyribonucleic acid (DNA) fragmentation in tumor-infiltrating lymphocytes (TILs) by the terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate nick end labeling (TUNEL) method. All canine mammary tumor cell lines expressed RCAS1 at both the messenger ribonucleic acid (mRNA) and protein level. Immunohistochemically, RCAS1 was negative in 100% of normal mammary glands, but was expressed in 100% of malignant tumors examined. In most malignant mammary tumors, RCAS1 was localized in the cytoplasm with no polarity of expression. In benign mammary tumors, it was detected on the luminal surface of the tumor cell. RCAS1 expression or localization was significantly correlated with malignancy. In situ DNA fragmentation of CD3-positive TILs was observed in RCAS1-expressing tumors. RCAS1-expressing tumors, indicating a possible induction of apoptotic cell death in TILs through RCAS1 expression. These observations suggest that RCAS1 probably plays an important role in tumor progression and escape from immune surveillance in canine mammary tumors. KEY WORDS: canine mammary tumor, DNA fragmentation, immunohistochemistry, receptor-binding cancer antigen expressed on SiSo cells (RCAS1), tumor infiltrating lymphocyte (TILs).

show abstract

The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus

Cited by 37 publications

References 12 publications

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

The Utility of Serum Receptor-Binding Cancer Antigen Expressed on Siso Cells in Gastrointestinal Tract Cancers

Expression of a Tumor-Associated Antigen, RCAS1, in Canine Mammary Tumors

Contact Info

Product

Resources

About